Comparing Treatments for Managing Lung Fluid in Cancer Patients

Efficacy of pleurodesis using Doxycycline 500mg, Doxycycline 1000mg and 4g Talc slurry in management of Malignant Pleural Effusion A pilot study. - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/04/085011

Enrollment

Registered

2025-04-16

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J910- Malignant pleural effusion

Interventions

Intervention1: Doxycycline 500mg: Tab. DOXYCYCLINE 500MG made into a 50ml solution using 0.9%NaCl intrapleural instillation through intercostal drainage tube- One time procedure which lasts for 15-

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed malignant pleural effusion cases

Exclusion criteria

Exclusion criteria: 1. Previously attempted and failed pleurodesis 2. Contraindications for pleurodesis 3. Contraindication for ICD tube placement 4. History of allergy to any tetracycline derivatives or talc. 5. Previous history of ARDS

Design outcomes

Primary

Measure	Time frame
To assess the success rates and complications of high-dose doxycycline 1000mg and talc slurry 4gm in comparison to a standard dose of doxycycline 500mg for pleurodesis in cases of malignant pleural effusionTimepoint: At the end of one week	—

Secondary

Measure	Time frame
To assess status of pleurodesisTimepoint: at the end of one month	—

Countries

India

Contacts

Public ContactDr. Saka Vinod Kumar

Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)

vinoddayamani@hotmail.com9442108095

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026